“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”
Recent News
- Physiogenex to present its obese NASH hamster model at the 20th World Congress of Insulin Resistance in Los Angeles, CA, Dec 1-3, 2022 11/29/2022
- Physiogenex to present its obese NASH hamster model at the 6th Obesity & NASH Summit in Boston, MA, Nov. 30- Dec. 1, 2022 11/22/2022
- Physiogenex to present its obese NASH hamster model at the AFDD Summit in Boston, MA, Nov. 10-11, 2022 11/09/2022
- Physiogenex to present its obese NASH hamster model at the AASLD Liver Meeting 2022 in Washington D.C., Nov. 4-8 10/28/2022
- Physiogenex to present its obese NASH hamster model at Drug Discovery on Target 2022 conference in Boston, MA, Oct 19 – 20th 10/14/2022
- Physiogenex to present its obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st) 09/27/2022